Key facts
- It has raised $5.1M; the latest was Later Stage VC ($2.1M) in Feb 2026.
- Notable investors include Tech Incubator Program for Startup, Bain Capital Ventures, New Paradigm Investment, Alternative Investment Management, BNK Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Leesol
- ·The full record, as it builds
Funding rounds
No funding rounds for Leesol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leesol
Developer of an Artificial Intelligence based neuromodulation technology designed to provide prevention and treatment for healthy brains. The company creates devices for improving sleep disorders and preventing dementia using Transcranial Alternating Current Stimulation (tACS) type cranial electrical stimulation, enabling patients with sleep disorders to enhance sleep quality, reduce stress, and support mental balance.
- Sector
- Healthcare
- HQ
- Busan, South Korea
- Founded
- 2017
- Employees
- 12
- Website
- leesolbrain.com/
- Ownership
- Privately Held (backing)
Leesol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leesol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leesol in its N-PORT filings yet. We sweep new filings monthly.